We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases.
We target the IGFBP3/TMEM219 axis, a novel pathway involved in cell apoptosis in the gut, pancreas and other organs which plays a key role in the development of Type 1 Diabetes and Inflammatory Bowel Disease.
Our discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway. Our lead program Ent001 is expected to enter Phase I clinical trials by 2021.